Advanced search
Publication Cover
Infection and Drug Resistance Volume 12, 2019 - Issue
Submit an article Journal homepage
100
Views
7
CrossRef citations to date
0
Altmetric
Original Research

Species Distribution And Antibiotic Susceptibility Of Nocardia Isolates From Yantai, China

Maoli Yi1 Department of Laboratory Medicine, Yantai Yuhuangding Hospital, Yantai, People’s Republic of China
,
Lipeng Wang1 Department of Laboratory Medicine, Yantai Yuhuangding Hospital, Yantai, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0001-8571-734X
ORCID Icon,
Weihao Xu1 Department of Laboratory Medicine, Yantai Yuhuangding Hospital, Yantai, People’s Republic of China
,
Li Sheng1 Department of Laboratory Medicine, Yantai Yuhuangding Hospital, Yantai, People’s Republic of China
,
Lihua Jiang1 Department of Laboratory Medicine, Yantai Yuhuangding Hospital, Yantai, People’s Republic of China
,
Fengzhen Yang1 Department of Laboratory Medicine, Yantai Yuhuangding Hospital, Yantai, People’s Republic of China
,
Qingmei Cao1 Department of Laboratory Medicine, Yantai Yuhuangding Hospital, Yantai, People’s Republic of China
&
Jinying Wu1 Department of Laboratory Medicine, Yantai Yuhuangding Hospital, Yantai, People’s Republic of ChinaCorrespondence[email protected]
 show all
Pages 3653-3661 | Published online: 22 Nov 2019

References

  • Fujita T, Ikari J, Watanabe A, Tatsumi K. Clinical characteristics of pulmonary nocardiosis in immunocompetent patients. J Infect Chemother. 2016;22(11):738–743. doi:10.1016/j.jiac.2016.08.00427615155
  • McTaggart LR, Doucet J, Witkowska M, Richardson SE. Antimicrobial susceptibility among clinical Nocardia species identified by multilocus sequence analysis. Antimicrob Agents Chemother. 2015;59(1):269–275. doi:10.1128/AAC.02770-1425348540
  • Martinez R, Reyes S, Menendez R. Pulmonary nocardiosis: risk factors, clinical features, diagnosis and prognosis. Curr Opin Pulm Med. 2008;14(3):219–227. doi:10.1097/MCP.0b013e3282f85dd318427245
  • Saubolle MA, Sussland D. Nocardiosis: review of clinical and laboratory experience. J Clin Microbiol. 2003;41(10):4497–4501. doi:10.1128/JCM.41.10.4497-4501.200314532173
  • Larruskain J, Idigoras P, Marimon JM, Perez-Trallero E. Susceptibility of 186 Nocardia sp. isolates to 20 antimicrobial agents. Antimicrob Agents Chemother. 2011;55(6):2995–2998. doi:10.1128/AAC.01279-1021402847
  • Lai CC, Liu WL, Ko WC, et al. Antimicrobial-resistant nocardia isolates, Taiwan, 1998–2009. Clin Infect Dis. 2011;52(6):833–835. doi:10.1093/cid/ciq25521367741
  • Uhde KB, Pathak S, McCullum I Jr., et al. Antimicrobial-resistant nocardia isolates, United States, 1995–2004. Clin Infect Dis. 2010;51(12):1445–1448. doi:10.1086/65298621058914
  • Huang L, Chen X, Xu H, et al. Clinical features, identification, antimicrobial resistance patterns of Nocardia species in China: 2009–2017. Diagn Microbiol Infect Dis. 2019;94(2):165–172. doi:10.1016/j.diagmicrobio.2018.12.00730679058
  • Wei M, Wang P, Yang C, Gu L. Molecular identification and phylogenetic relationships of clinical Nocardia isolates. Antonie Van Leeuwenhoek. 2019. doi:10.1007/s10482-019-01296-2
  • Tremblay J, Thibert L, Alarie I, Valiquette L, Pepin J. Nocardiosis in Quebec, Canada, 1988–2008. Clin Microbiol Infect. 2011;17(5):690–696. doi:10.1111/j.1469-0691.2010.03306.x20636427
  • Clinical and Laboratory Standards Institude (CLSI). Susceptibility Testing Of Mycobacteria, Nocardiae, And Other Aerobic Actinomycetes; Approved Standard M24–2nd Edition. Wayne, PA, USA: CLSI; 2011.
  • Brown-Elliott BA, Brown JM, Conville PS, Wallace RJ Jr. Clinical and laboratory features of the Nocardia spp. based on current molecular taxonomy. Clin Microbiol Rev. 2006;19(2):259–282. doi:10.1128/CMR.19.2.259-282.200616614249
  • Munoz J, Mirelis B, Aragon LM, et al. Clinical and microbiological features of nocardiosis 1997–2003. J Med Microbiol. 2007;56(Pt 4):545–550. doi:10.1099/jmm.0.46774-017374898
  • Cercenado E, Marin M, Sanchez-Martinez M, Cuevas O, Martinez-Alarcon J, Bouza E. In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods. Antimicrob Agents Chemother. 2007;51(3):1102–1104. doi:10.1128/AAC.01102-0617194827
  • Wang HK, Sheng WH, Hung CC, et al. Clinical characteristics, microbiology, and outcomes for patients with lung and disseminated nocardiosis in a tertiary hospital. J Formos Med Assoc. 2015;114(8):742–749. doi:10.1016/j.jfma.2013.07.01724008153
  • Valdezate S, Garrido N, Carrasco G, et al. Epidemiology and susceptibility to antimicrobial agents of the main Nocardia species in Spain. J Antimicrob Chemother. 2017;72(3):754–761. doi:10.1093/jac/dkw48927999029
  • Hashemi-Shahraki A, Heidarieh P, Bostanabad SZ, et al. Genetic diversity and antimicrobial susceptibility of Nocardia species among patients with nocardiosis. Sci Rep. 2015;5:17862. doi:10.1038/srep1786226638771
  • David N, Moellering RC. The Sanford Guide to Antimicrobial Therapy. Sperryvile, VA, USA: Antimicrobial Therapy; 2018.
  • Lebeaux D, Bergeron E, Berthet J, et al. Antibiotic susceptibility testing and species identification of Nocardia isolates: a retrospective analysis of data from a French expert laboratory, 2010–2015. Clin Microbiol Infect. 2019;25(4):489–495. doi:10.1016/j.cmi.2018.06.01329933049

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.